Research opens door to new drug therapies for Parkinson’s disease
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson’s disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and Dr. Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin.
What is Parkinson’s Disease?
Parkinson’s disease is a neurological condition related to the death of specific brain cells that produce dopamine, a chemical needed for brain cells to control muscular movement. In Parkinson’s disease, dopamine-producing cells stop functioning for reasons still unknown.
November 27, 2012 - Clinician-scientists take a unique, integrated approach that is essential to advancing science and medicine. Problems encountered in the clinic inspire research and new findings from the labs are directly applied to patients’ needs. The integrated model is a hallmark of the Montreal Neurological Institute and Hospital – The Neuro, at McGill University and the MUHC and is now being replicated worldwide.